OBD and major US Pharma sign agreement to differentiate Alzheimer’s disease (AD) patients from other cognitive impaired patients.

OBD will identify epigenetic changes based on chromosome conformation signatures that will be able to identify Alzheimer’s disease (AD) patients from whole blood using OBD’s EpiSwitch™ Discovery Platform.